Krystal Biotech, Inc.

{
  "main_header": {
    "sid": 1245865,
    "name": "Krystal Biotech, Inc.",
    "stock_name": "Krystal Biotech, Inc.",
    "full_name": "Krystal Biotech, Inc.",
    "name_url": "stocks-analysis/krystal-biotech-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "272.74",
    "chg": 5.1,
    "chgp": "1.91%",
    "dir": 1,
    "prev_price": "267.64",
    "mcapval": "8,293.29",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US5011471027",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "262.25 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/krystal-biotech-inc-1245865-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/krystal-biotech-receives-upgrade-to-strong-buy-following-valuation-improvement-3690051",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrystalBiotechI_mojoScore_3690051.png",
        "date": "2025-11-11 16:37:05",
        "description": "Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3689276",
        "imagepath": "",
        "date": "2025-11-11 11:33:51",
        "description": "As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price.\n\nIn comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market...."
      }
    ],
    "total": 21,
    "sid": "1245865",
    "stock_news_url": "https://www.marketsmojo.com/news/krystal-biotech-inc-1245865"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

2025-11-11 16:37:05

Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth.

Read full news article

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-11-11 11:33:51

As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price. In comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market....

Read full news article

View All News